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Abstract
Purpose Sotatercept may represent a novel approach to the
treatment of chemotherapy-induced anemia (CIA). We report
the results from two phase 2 randomized studies examining
the use of sotatercept for the treatment of CIA in patients with
metastatic cancer.
Methods In study A011-08, patients with metastatic breast
cancer were randomized to 2:2:2:1 to receive sotatercept 0.1,
0.3, or 0.5 mg/kg, or placebo, respectively, every 28 days. In
study ACE-011-NSCL-001, patients with solid tumors treated
with platinum-based chemotherapy received sotatercept 15 or
30 mg every 42 days. The primary endpoint for both studies
was hematopoietic response, defined as a hemoglobin (Hb)
increase of ≥1 g/dL from baseline.
Results Both studies were terminated early due to slow patient
accrual. Among patients treated with sotatercept in the A011-
08 and ACE-011-NSCL-001 studies, more patients achieved a
mean Hb increase of ≥1 g/dL in the combined sotatercept
0.3 mg/kg and 15 mg (66.7 %) group and sotatercept
0.5 mg/kg and 30 mg (38.9 %) group versus the sotatercept
0.1 mg/kg (0 %) group. No patients achieved a mean Hb
increase of ≥1 g/dL in the placebo group. The incidence of
treatment-related adverse events (AEs) was low in both stud-
ies, and treatment discontinuations due to AEs were
uncommon.
Conclusions Although both studies were terminated early,
these results indicate that sotatercept is active and has an ac-
ceptable safety profile in the treatment of CIA.
Keywords ActRIIA . Chemotherapy-induced anemia .
Erythropoiesis . Sotatercept
Introduction
Chemotherapy-induced anemia (CIA) is a common complica-
tion in patients treated with myelosuppressive chemotherapy
[1, 2]. Anemia is associated with fatigue, reduced functional
ability, and impaired quality of life [1, 3].
Current treatment options for CIA include red blood cell
(RBC) transfusions and erythropoiesis-stimulating agents
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(ESAs); however, both treatment types are associated with an
increased risk of thrombotic events [2]. In addition, ESAsmay
be associated with possible decreased survival and shortened
time to tumor progression in patients with cancer, and RBC
transfusions carry a risk of infection, transfusion-related reac-
tions, and possible decreased survival [2, 4–6]. Given these
safety concerns, novel treatment options for CIA that are effi-
cacious and safe are needed.
Sotatercept (ACE-011) is a recombinant fusion protein
composed of the extracellular domain of the human activin
receptor type IIA (ActRIIA) and the fragment crystallizable
(Fc) domain of the human immunoglobulin G1 antibody [7].
Animal models and in vitro human models using RAP-011,
the murine ortholog of sotatercept, have shown that
sotatercept improves RBC parameters by stimulation of late-
stage erythropoiesis [7]. This mechanism of action is marked-
ly different from that of ESAs, which act on earlier stages of
erythroid development [7, 8]. Sotatercept is thought to act by
trapping growth differentiation factor (GDF)-11, a ligand that
binds to ActRIIA and impedes terminal erythroid maturation
[7, 9]. A related ligand trap fusion protein, luspatercept (ACE-
536), has also been shown to promote maturation of late-stage
erythroid precursors via a similar pathway [10].
Administration of sotatercept or RAP-011 has been shown
to increase hemoglobin (Hb) and hematocrit levels in animal
models and in healthy postmenopausal women [7, 9, 11–14];
these findings have promoted interest in sotatercept as a po-
tential treatment for patients with anemia and other diseases
characterized by ineffective erythropoiesis. In a mouse model
of CIA, RAP-011 has similar effects on Hb and hematocrit
[14].
Here we report the results from two phase 2 randomized
studies (A011-08 and ACE-011-NSCL-001) evaluating the
effects of sotatercept for the treatment of CIA. Studies
A011-08 and ACE-011-NSCL-001 were performed in pa-
tients with CIA, and both studies were of similar design.
Methods
Both studies were conducted according to good clinical prac-
tice and the ethical principles outlined in the 1964 Declaration
of Helsinki. All patients in both studies provided written in-
formed consent prior to their inclusion in the studies.
Study designs
A011-08 was a phase 2, double-blind, randomized, placebo-
controlled study, which assessed the efficacy, safety, and tol-
erability of sotatercept for the treatment of CIA in patients
with metastatic breast cancer. ACE-011-NSCL-001 was a
phase 2a, open-label, randomized, dose-ranging study to eval-
uate the efficacy and safety of sotatercept for the treatment of
CIA in patients with advanced or metastatic solid tumors treat-
ed with platinum-based chemotherapy. Both trials are regis-
tered at www.ClinicalTrials.gov, A011-08 as NCT00931606
and ACE-011-NSCL-001 as NCT01284348. The data cutoff
dates for studies A011-08 and ACE-011-NSCL-001 were No-
vember 18, 2010 and January 29, 2013, respectively.
Adult patients with metastatic breast cancer who were un-
dergoing treatment with a myelosuppressive chemotherapy
regimen, and who were expected to continue treatment for
≥9 weeks after initiation of study treatment, were eligible for
inclusion in study A011-08. Adult patients with solid tumors
and advanced ormetastatic disease whowere undergoing non-
curative treatment with platinum-based chemotherapy were
eligible for inclusion in study ACE-011-NSCL-001.
Chemotherapies were administered according to the stan-
dard of care of each study site and included anthracycline,
taxane, gemcitabine, vinorelbine, or capecitabine. For both
studies, eligible patients were required to have a baseline Hb
level between ≥6.5 and <11.0 g/dL. Eligible patients were also
required to have had no ESA treatment in the previous 30 days
for study A011-08 or in the previous 28 days for study ACE-
011-NSCL-001. Patients were required to have received no
RBC transfusion in the previous 7 days for study A011-08
or in the previous 14 days for study ACE-011-NSCL-001.
Patients in both studies were required to have received≤2 units
of transfused blood in the previous 30 days prior to study start.
Patients in study A011-08 who had received >5 prior chemo-
therapy regimens (not including the current regimen) were
excluded.
In study A011-08, patients were randomized to 2:2:2:1 to
0.1, 0.3, or 0.5 mg/kg sotatercept or to placebo, respectively;
treatment was administered subcutaneously every 28 days for
a maximum of four doses. Planned enrollment was 30 patients
to each of the three sotatercept treatment groups and 15 pa-
tients to the placebo group. In study ACE-011-NSCL-001,
patients were randomized to 15 or 30 mg of sotatercept, which
was administered subcutaneously every 42 days, for a maxi-
mum of four doses; the dose schedule was chosen based on
the onset and duration of Hb response to sotatercept in previ-
ous studies, as well as to accommodate common dosing
schedules for platinum-based chemotherapy. Planned enroll-
ment was up to a maximum of 30 patients, with 10–15 patients
in each treatment group.
Analysis of studies
For this analysis, patients who were randomized to either
sotatercept 0.3 mg/kg in study A011-08 or sotatercept 15 mg
in study ACE-011-NSCL-001 have been included in a com-
bined 0.3 mg/kg and 15 mg dose group based on an approx-
imate body weight of 50–60 kg. Patients randomized to either
sotatercept 0.5 mg/kg in study A011-08 or sotatercept 30 mg
in study ACE-011-NSCL-001 have also been included in a
1518 Support Care Cancer (2016) 24:1517–1525
combined sotatercept 0.5 mg/kg and 30 mg dose group. All
these dose levels were considered equivalent and combined
for analysis and reporting.
Dose modification
Dose modification rules were based on Hb concentrations and
blood pressure readings since the last treatment (Fig. 1). Pa-
tients in study A011-08 were discontinued from treatment if
they experienced drug-related toxicity of grade ≥3, with the
exception of patients with grade 3 hypertension that had de-
creased to grade ≤1 within 7 days of receiving antihyperten-
sive therapy. Patients in study ACE-011-NSCL-001 who ex-
perienced an Hb increase ≥3 g/dL sustained for a 28-day pe-
riod received a dose reduction of two levels; of these patients,
those who experienced a second Hb increase of ≥3 g/dL were
discontinued from treatment. Patients in study ACE-011-
NSCL-001 were also discontinued from treatment if their
Hb increased to >15 g/dL, sustained for a 7-day period,
whereas patients in study A011-08 with an Hb concentration
above the upper limit of normal were discontinued from
treatment.
Study endpoints and definition of study population
For study A011-08, the modified intent-to-treat (mITT) pop-
ulation and safety population included all randomized patients
who received ≥1 dose of study treatment. All analyses for
study ACE-011-NSCL-001 were performed on the population
of treated patients, defined as randomized patients who re-
ceived ≥1 dose of sotatercept.
Per protocol, the primary endpoint for study A011-08 was
hematopoietic response (defined as an Hb increase from base-
line of ≥1 g/dL for 28 consecutive days during the treatment
period and up to 2 months after the last dose of study treatment
in the absence of RBC transfusion or treatment with an ESA).
In study ACE-011-NSCL-001, efficacy was also assessed by
hematopoietic response, defined as an increase in Hb ≥1 g/dL
A011-08: <2 g/dL increase within 28-day period since 
last treatment day
ACE-011-NSCL-001: <2 g/dL increase within a dosing 
period or a ≥2 g/dL increase not sustained for a 28-day 
period since last dosing day
A011-08: ≥2 g/dL increase within 28-day period since 
last treatment day
ACE-011-NSCL-001: ≥2 g/dL increase sustained for a 
28-day period since last dosing day
A011-08: <2 g/dL increase within 28-day period since last 
treatment day
ACE-011-NSCL-001: <2 g/dL increase within a dosing 
period or a ≥2 g/dL increase not sustained for a 28-day 
period since last dosing day
A011-08: ≥2 g/dL increase within 28-day period since last 
treatment day
ACE-011-NSCL-001: ≥2 g/dL increase sustained for a 28-







followed by dose 
reduction
Hb <11 g/dL (per 
local laboratory 
value)
Hb ≥11 g/dL (per 
local laboratory 
value)
A011-08: hypertension grade 2
ACE-011-NSCL-001: hypertension SBP ≥150 mmHg or  
DBP ≥100 mmHg
Dose interruption, 
followed by dose 
reduction
A011-08: hypertension grade 3
ACE-011-NSCL-001: <1 g/dL increase, 
SBP <150 mmHg, DBP <100 mmHg
Dose escalation 
Fig. 1 Sotatercept dose-
modification rules for studies
A011-08 and ACE-011-NSCL-
001. DBP diastolic blood
pressure, Hb hemoglobin, SBP
systolic blood pressure
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from baseline that was maintained for 4 consecutive weeks in
the absence of RBC transfusions and/or treatment with ESAs.
For this analysis, the proportion of patients achieving a mean
Hb increase from baseline of ≥1 g/dL is reported for the com-
bined A011-08 and ACE-011-NSCL-001 study populations;
mean Hb increases were calculated from the first dose re-
ceived until the end of the study period.
Secondary endpoints for study A011-08 included hemato-
poietic response (Hb increase of ≥2 g/dL and Hb concentra-
tion ≥11 g/dL sustained for 28 consecutive days), time to
achieve hematopoietic response, duration of hematopoietic
response, the proportion of patients requiring RBC transfusion
and/or treatment with an ESA, and safety. Exploratory end-
points for ACE-011-NSCL-001 included the evaluation of the
duration of hematopoietic response, assessment of renal func-
tion biomarkers, and evaluation of quality of life and bone
metabolism. Safety was evaluated in A011-08 using the safety
population, whereas all other secondary endpoints for A011-
08 were evaluated in the mITT population. Adverse events
(AEs) were recorded according to National Cancer Institute
Common Terminology Criteria for Adverse Events guidelines
version 3.0 and version 4.0 for the A011-08 and ACE-011-
NSCL-001 studies, respectively.
Results
Both studies were terminated early due to slower than expect-
ed patient accrual rates. Accrual rates were slower than ex-
pected due to recent substantial changes in the standard of care
for patients with cancer and anemia. Therefore, all analyses
presented are exploratory.
Patients
Of 55 patients enrolled in the two studies, 5 patients received
placebo and 50 patients received ≥1 dose of sotatercept: 8
patients received sotatercept 0.1 mg/kg, 24 patients received
either sotatercept 0.3 mg/kg or 15 mg, and 18 patients re-
ceived either sotatercept 0.5 mg/kg or 30 mg. A total of 30
patients were enrolled as part of study A011-08 and 25 pa-
tients were enrolled and received ≥1 dose of study treatment in
study ACE-011-NSCL-001.
Baseline characteristics are presented in Table 1. For pa-
tients treated with sotatercept, median age was 57 years
(range 22–81 years), 39 patients (78.0 %) were female,
and median Hb level at baseline was 9.0 g/dL (range 6.3–
11.0). Prior and concomitant antineoplastic use is presented
in Table 2; carboplatin was the most frequently adminis-
tered concurrent chemotherapy regimen in patients treated
with sotatercept.
Efficacy
Efficacy results are presented in Table 3. A mean Hb increase
of ≥1 g/dL was observed for 7 of 18 patients (38.9 %) in the
combined sotatercept 0.5 mg/kg and 30mg dose groups, 16 of
24 patients (66.7 %) in the combined sotatercept 0.3 mg/kg
and 15 mg dose groups, 0 of 8 patients in the sotatercept
0.1 mg/kg dose group, and 0 of 5 patients treated with
placebo.
A mean increase in Hb levels ≥2 g/dL was observed in 2 of
18 patients (11.1 %) in the combined sotatercept 0.5 mg/kg
and 30 mg dose group, 2 of 24 patients (8.3 %) in the com-
bined sotatercept 0.3 mg/kg and 15 mg dose group, 0 of 8
patients in the sotatercept 0.1 mg/kg dose group, and 0 of 5
patients treated with placebo (Fig. 2).
Of the 13 non-responders who received sotatercept in study
A011-08, 5 patients (38.5 %) had ≥1 dose interruption or
reduction. In four of these patients (80.0 %), an initial Hb
increase of ≥1 g/dL from baseline on or before day 29 had
been documented; however, following interruption/reduction
of the second sotatercept dose, the initial Hb increase was not
sustained. Mean Hb level increase following the first dose of
study treatment peaked at approximately 15 days after admin-
istration in the 0.3 and 0.5 mg/kg dose groups, before decreas-
ing to near baseline levels by day 29.
Overall, 18 patients (36.0 %) administered sotatercept re-
quired either RBC transfusion or ESAs during the studies
reported herein: 9 patients (50.0 %) in the combined
sotatercept 0.5 mg/kg and 30 mg group, 8 patients (33.3 %)
in the combined sotatercept 0.3 mg/kg and 15mg group, and 1
patient (12.5 %) patient in the sotatercept 0.1 mg/kg group.
Due to the small number of responses, median time to re-
sponse was not evaluable.
Safety
Of the 50 patients who received sotatercept, 10 (20.0 %) re-
ceived the planned four doses of study drug: 2 patients
(11.1 %) in the combined 0.5 mg/kg and 30 mg dose groups,
7 patients (29.2%) in the combined 0.3 mg/kg and 15mg dose
groups, and 1 patient (12.5 %) in the 0.1 mg/kg dose group. A
further 8 patients (16.0 %) received three doses of sotatercept,
26 patients (52.0 %) received two doses, and 6 patients
(12.0 %) received one dose.
AEs were reported in 44 patients (88.0 %) and 5 pa-
tients (100 %) administered sotatercept and placebo, re-
spectively (Table 4). Grade ≥3 AEs were reported in 35
patients (70.0 %) and 4 patients (80.0 %) administered
sotatercept and placebo, respectively. The most commonly
reported grade ≥3 AEs occurring in more than 10 % of
patients were anemia, neutropenia, and thrombocytopenia
in sotatercept-treated patients and neutropenia in placebo-
treated patients. One patient in the combined sotatercept
1520 Support Care Cancer (2016) 24:1517–1525
Table 1 Baseline characteristics for patients with metastatic breast cancer (study A011-08 mITT population) and patients with advanced or metastatic







and 15 mg (n=24)
Sotatercept 0.5 mg/kg
and 30 mg (n=18)
Total sotatercept
(N=50)
Age, median (range; years) 52 (32–61) 51 (38–70) 57 (22–81) 66 (35–80) 57 (22–81)
Female, n (%) 5 (100) 8 (100) 18 (75.0) 13 (72.2) 39 (78.0)
Hb level, median (range; g/dL) 9.9 (8.9–10.7) 9.7 (7.5–11.0) 9.0 (6.3–11.0)a 8.8 (7.2–10.6) 9.0 (6.3–11.0)a
Disease stage at diagnosis, n (%)
I 1 (20.0) 3 (37.5) 0 1 (5.6) 4 (8.0)
II 0 1 (12.5) 5 (20.8) 2 (11.1) 8 (16.0)
III 2 (40.0) 3 (37.5) 5 (20.8) 3 (16.7) 11 (22.0)
IV 2 (40.0) 1 (12.5) 11 (45.8) 8 (44.4) 20 (40.0)
Unknown 0 0 3 (12.5) 4 (22.2) 7 (14.0)
Malignancy, n (%)
Breast 5 (100) 8 (100) 10 (41.7) 7 (38.9) 25 (50.0)
NSCLC 0 0 11 (45.8) 7 (38.9) 18 (36.0)
SCLC 0 0 2 (8.3) 3 (16.7) 5 (10.0)
Otherb 0 0 1 (4.2) 1 (5.6) 2 (4.0)
Hb hemoglobin, mITT modified intent-to-treat, NSCLC non-small-cell lung cancer, SCLC small-cell lung cancer
a Hb data are missing for one patient in the sotatercept 0.5 mg/kg and 30 mg dose group
b Includes invasive malignant epithelioid mesothelioma (n=1) and adenocarcinoma (n=1)
Table 2 Summary of prior and concurrent antineoplastic therapy use in patients with metastatic breast cancer (study A011-08) and for patients with







and 15 mg (n=24)
Sotatercept 0.5 mg/kg
and 30 mg (n=18)
Total sotatercept
(N=50)
Carboplatin 0 1 (12.5) 12 (50.0) 7 (38.9) 20 (40.0)
Gemcitabine 1 (20.0) 3 (37.5) 5 (20.8) 6 (33.3) 14 (28.0)
Cisplatin 0 0 5 (20.8) 6 (33.3) 11 (22.0)
Paclitaxel 1 (20.0) 1 (12.5) 7 (29.2) 2 (11.1) 10 (20.0)
Doxorubicin 1 (20.0) 2 (25.0) 2 (8.3) 4 (22.2) 8 (16.0)
Bevacizumab 1 (20.0) 0 6 (25.0) 1 (5.6) 7 (14.0)
Pemetrexed 0 0 5 (20.8) 2 (11.1) 7 (14.0)
Etoposide 0 0 2 (8.3) 4 (22.2) 6 (12.0)
Docetaxel 3 (60.0) 3 (37.5) 3 (12.5) 0 6 (12.0)
Trastuzumab 0 1 (12.5) 1 (4.2) 1 (5.6) 3 (6.0)
Vinorelbine 1 (20.0) 1 (12.5) 2 (8.3) 0 3 (6.0)
Capecitabine 1 (20.0) 0 1 (4.2) 1 (5.6) 2 (4.0)
Cyclophosphamide 0 1 (12.5) 0 1 (5.6) 2 (4.0)
Fluorouracil 0 0 0 1 (5.6) 1 (2.0)
Mitomycin 0 1 (12.5) 0 0 1 (2.0)
Mitoxantrone 0 1 (12.5) 0 0 1 (2.0)
Tegafur 0 1 (12.5) 0 0 1 (2.0)
Vinblastine 0 0 0 1 (5.6) 1 (2.0)
Oxaliplatin 0 0 0 1 (5.6) 1 (2.0)
All patients had received prior or concurrent treatment with antineoplastic agents
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0.5 mg/kg and 30 mg dose groups reported a grade ≥3
thrombotic event (cerebrovascular accident). AEs related
to study treatment were reported in 11 patients (22.0 %)
treated with sotatercept.
Overall, 18 patients (36.0 %) died: 8 patients died in
the combined sotatercept 0.5 mg/kg and 30 mg dose
groups, 9 patients died in the combined sotatercept
0.3 mg/kg and 15 mg dose groups, and 1 patient died in
the sotatercept 0.1 mg/kg dose group; no patient died in
the placebo group. Cause of death was reported as disease
progression for 16 patients and unknown causes for 2
patients (a 57-year-old female in the combined 0.3 mg/kg
and 15 mg dose group and a 72-year-old female in the
combined 0.5 mg/kg and 30 mg dose group). Four deaths
occurred during the on-treatment period, all due to disease
progression; the remaining 14 deaths all occurred more
than 30 days after the last dose of sotatercept. No
treatment-related deaths were reported, and no AEs lead-
ing to death were considered study-drug-related.
Of the 50 patients who received sotatercept, 19
(38.0 %) had ≥1 dose interruption or reduction during
the study treatment period per protocol. A total of eight
patients (44.4 %) in the combined sotatercept 0.5 mg/kg
and 30 mg dose groups, seven patients (29.2 %) in the
combined sotatercept 0.3 mg/kg and 15 mg dose
groups, and four patients (50 %) in the 0.1 mg/kg dose
group had ≥1 dose interruption or reduction; a further
three patients (60.0 %) treated with placebo had ≥1
dose interruption or reduction. Dose delay or interrup-
tion due to AEs was experienced by three patients
(16.7 %) in the combined sotatercept 0.5 mg/kg and
30 mg dose group: one patient experienced thrombocy-
topenia, one patient experienced hypertension, and one
patient experienced pathologic fractures.
Treatment discontinuation as a result of AEs occurred
in eight patients (16.0 %) treated with sotatercept: six
patients in the combined 0.5 mg/kg and 30 mg dose
groups (metastatic breast cancer, tumor hemorrhage,
gastric ulcer perforation, pathological fracture, grade 3
muscular weakness, and grade 1 malignant mediastinal
neoplasm), one patient in the combined 0.3 mg/kg and
15 mg dose groups (grade 3 acute renal failure), and
one patient in the 0.1 mg/kg dose group (anemia)—
none was considered to be related to study treatment.
Treatment was discontinued for one patient (20.0 %)
treated with placebo (fatigue).
Table 3 Rates of hematopoietic responses among patients with metastatic breast cancer (study A011-08 mITT population) and patients with advanced







and 15 mg (n=24)
Sotatercept 0.5 mg/kg




Mean Hb increase ≥1 g/dL 0 0 16 (66.7) 7 (38.9) 23 (46.0)
Mean Hb increase ≥2 g/dL 0 0 2 (8.3) 2 (11.1) 4 (8.0)
Hb concentration ≥11 g/dL 3 (60.0) 2 (25.0) 15 (62.5) 6 (33.3) 23 (46.0)







≥1 g/dL ≥2 g/dL
Placebo
Sotatercept 0.1 mg/kg
Sotatercept 0.3 mg/kg and 15 mg
Sotatercept 0.5 mg/kg and 30 mg
0 %
Mean change in Hb level from baseline














Fig. 2 Mean change in Hb level
from baseline for patients with
metastatic breast cancer (study
A011-08 mITT population) and
patients with advanced or
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Discussion
Sotatercept has multiple direct and indirect hematologic ef-
fects that may contribute to its ability to improve the symp-
toms of anemia [15–18].
In a previous study of healthy postmenopausal women,
sotatercept administration was associated with marked in-
creases in Hb, hematocrit, and RBC counts; sotatercept has
been suggested as a potential treatment for patients with inef-
fective erythropoiesis [13]. Furthermore, preliminary data
from another study have demonstrated evidence of sotatercept
activity in patients with β-thalassemia, a condition in which
ESAs are generally ineffective [8, 19]. These data suggest a
mechanism of action for sotatercept distinct from that of ESAs
and, therefore, raise the possibility of its use in other disease
areas.
The two phase 2 studies described herein evaluated
sotatercept as a potential treatment for CIA. The studies were
of a similar design, with similar endpoints, populations, and
dose-modification rules. A mean Hb increase from baseline of
≥1 g/dL was observed in 46 % of sotatercept-treated patients
with CIA, whether they had metastatic breast cancer (study
A011-08) or metastatic solid tumors (study ACE-011-NSCL-
001). Higher response rates were generally reported in the
combined sotatercept 0.3 mg/kg and 15 mg dose group and
the combined sotatercept 0.5 mg/kg and 30 mg dose group
versus the sotatercept 0.1 mg/kg group, suggesting a possible
dose–response relationship.
In both studies, sotatercept was well tolerated in patients
with CIA; safety findings were comparable to placebo and
were generally consistent with the disease under study [11,
13]. The incidence of treatment-related AEs was low in both
studies, and treatment discontinuations due to AEs were com-
parable to placebo. A single grade ≥3 thrombotic event was
reported in the combined sotatercept 0.5 mg/kg and 30 mg
dose group. Other treatment options for CIA, including ESAs
and RBC transfusion, are associated with an increased risk of
thrombotic events [2]. More deaths were reported in the
sotatercept treatment groups versus the placebo group; the
majority of deaths were due to disease progression. Given
the small number of patients in the placebo group, mortality
rates in the placebo and sotatercept treatment groups could not
be meaningfully compared. The generally favorable safety
profile of sotatercept highlights its potential as an alternative
to ESAs in the treatment of CIA. However, due to the small
number of patients enrolled and the limited follow-up data
available, it was not possible to assess the effect of sotatercept
on tumor progression.
There are several limitations to these studies. It is likely that
the dose-modification rules used may have resulted in patients








and 15 mg (n=24)
Sotatercept 0.5 mg/kg
and 30 mg (n=18)
Total sotatercept
(N=50)
Patients with ≥1 AE 5 (100) 6 (75.0) 21 (87.5) 17 (94.4) 44 (88.0)
Patients with ≥1 AE related to treatmenta 1 (20.0) 2 (25.0) 5 (20.8) 4 (22.2) 11 (22.0)
Patients with ≥1 SAE 1 (20.0) 0 6 (25.0) 11 (61.1) 17 (34.0)
Patients with ≥1 AE grade ≥3 4 (80.0) 5 (62.5) 14 (58.3) 16 (88.9) 35 (70.0)
Grade ≥3 AEs occurring in ≥10 % of patients
Anemia 1 (20.0) 1 (12.5) 5 (20.8) 6 (33.3) 12 (24.0)
Neutropenia 3 (60.0) 4 (50.0) 2 (8.3) 6 (33.3) 12 (24.0)
Leukopenia 2 (40.0) 3 (37.5) 1 (4.2) 0 4 (8.0)
Thrombocytopenia 0 1 (12.5) 4 (16.7) 7 (38.9) 12 (24.0)
Asthenia 1 (20.0) 1 (12.5) 1 (4.2) 3 (16.7) 5 (10.0)
Dehydration 0 0 3 (12.5) 0 3 (6.0)
Febrile neutropenia 0 0 0 2 (11.1) 2 (4.0)
Fatigue 1 (20.0) 0 2 (8.3) 2 (11.1) 4 (8.0)
Hypomagnesemia 0 0 0 2 (11.1) 2 (4.0)
Non-small cell lung cancer 0 0 1 (4.2) 2 (11.1) 3 (6.0)
Patients with AEs leading to treatment
discontinuation
1 (20.0) 1 (12.5) 1 (4.2) 6 (33.3) 8 (16.0)
AE adverse event, SAE serious AE
aDefined as possibly, probably, or definitely treatment-related, as assessed by the investigator
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whowould otherwise have achieved a hematopoietic response
being categorized as non-responders; indeed, the majority of
patients who had a dose interruption or reduction in study
A011-08 achieved an initial Hb increase from baseline of
≥1 g/dL that was not sustained after dose modification.
Although the optimal dose and schedule of sotatercept for
the treatment of CIA has not been established, it is likely that
the dose scheduling employed in our studies may have affect-
ed outcomes. The two studies reported herein used dosing
intervals of 28 and 42 days, respectively; the dosing schedules
used were selected based on preliminary pharmacokinetics
and pharmacodynamics data from healthy volunteers treated
with sotatercept; mean terminal half-life after subcutaneous
multiple dose administration of sotatercept was approximately
23 days, and Hb increase was sustained until ≥2 months after
the last dose of sotatercept. Previous studies involving healthy
volunteers have also shown sustained Hb increases associated
with subcutaneous administration of sotatercept once every
28 days [13]. However, Hb increases peaked 15 days after
administration of the first dose of study treatment in study
A011-08, with a decrease to baseline levels by day 29, sug-
gesting that the lack of a sustained Hb response may be due to
the dosing schedule used. Most patients in study ACE-011-
NSCL-001 had a hematological response, although responses
did not always meet study criteria and were not sustained.
These results suggest that shorter dosing intervals may be
beneficial in future studies.
Based on preliminary pharmacokinetics and pharmacody-
namics data from healthy volunteers, the doses administered
in these studies did not exceed 0.5 mg/kg administered once
every 28 days. However, subsequent ongoing studies with
sotatercept have exceeded this dose: patients with anemia
are currently undergoing treatment with sotatercept
>1 mg/kg administered once every 3 weeks, with no dose-
limiting toxicities, and the maximum tolerated dose has not
yet been reached. It is possible, therefore, that the sotatercept
doses used herein may be beneath an optimal threshold.
The use of concomitant chemotherapy regimens was not
controlled for in either study and may have potentially affect-
ed study outcomes.
Both of the reported studies were terminated early due to
slow patient accrual as a result of significant changes in the
recommended treatment of CIA, as opposed to insufficient
efficacy or safety concerns. Consequently, the number of pa-
tients enrolled was small and the findings should be
interpreted with caution.
Despite these limitations, the available data provide in-
sights into the potential clinical efficacy and safety of
sotatercept in the treatment of CIA. The results of these studies
indicate that sotatercept is active and has an acceptable safety
profile when used in the treatment of CIA. Furthermore, pre-
liminary data from phase 2 trials of sotatercept for the treat-
ment of anemia in patients with diseases characterized by
ineffective erythropoiesis, including β-thalassemia and
myelodysplastic syndromes, are encouraging, further
supporting the clinical potential of sotatercept [19, 20].
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